FDA places clinical hold on Concert Pharma's hair loss drug

(Reuters) - Concert Pharmaceuticals Inc said on Wednesday the U.S. Food and Drug Administration imposed a clinical hold on a mid-stage trial testing the company's drug to treat alopecia areata, a type of hair loss.